Management of individuals requiring antiretroviral therapy and TB treatment

Current Opinion in HIV and AIDS

Volumn 5, Issue 1, 2010, Pages 61-69

  Cohen, Karen ^a   Meintjes, Graeme ^b,c,d  

^a Division of Clinical Pharmacology

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d GF Jooste Hospital   (South Africa)

Author keywords

Antiretroviral therapy; ART; HIV; Immune reconstitution inflammatory syndrome; IRIS; TB; Tuberculosis

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; CAPREOMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSERINE; DIDANOSINE; EFAVIRENZ; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PROTEINASE INHIBITOR; PYRAZINAMIDE; PYRIDOXINE; RIFABUTIN; RIFAMPICIN; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOCOMPROMISED PATIENT; LENGTH OF STAY; LIVER TOXICITY; MIXED INFECTION; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROPATHY; OPTIMAL DRUG DOSE; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SURGICAL DRAINAGE; SURVIVAL RATE; TERATOGENICITY; TUBERCULOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; DRUG INTERACTIONS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MYCOBACTERIUM TUBERCULOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVERSE TRANSCRIPTASE INHIBITORS; TUBERCULOSIS;

EID: 74349092165     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283339309     Document Type: Review

References (92)

1. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20:1605-1612.
2. Baalwa J, Mayanja-Kizza H, Kamya MR, et al. Worsening and unmasking of tuberculosis in HIV-1 infected patients after initiating highly active antiretroviral therapy in Uganda. Afr Health Sci 2008; 8:190-195.
3. Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS 2009; 4:325-333.
4. Scano F, Vitoria M, Burman W, et al. Management of HIV-infected patients with MDR- and XDR-TB in resource-limited settings. Int J Tuberc Lung Dis 2008; 12:1370-1375.
5. Coyne KM, Pozniak AL, Lamorde M, Boffito M. Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents. AIDS 2009; 23:437-446.
6. McIlleron H, Meintjes G, Burman WJ, Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immunereconstitution inflammatory syndrome. J InfectDis 2007;196 (Suppl 1): S63-S75.
7. Burman WJ. Issues in the management of HIV-related tuberculosis. Clin Chest Med 2005; 26:283-294; vi-vii.
8. de Jong BC, Israelski DM, Corbett EL, Small PM. Clinical management of tuberculosis in the context of HIV infection. Annu Rev Med 2004; 55:283-301.
9. Harries AD, Zachariah R, Lawn SD. Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa. Int J Tuberc Lung Dis 2009; 13:6-16.
10. Niemi M, Backman JT, Fromm MF, et al. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003; 42:819-850.
11. Centers for Disease Control and Prevention. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis. CDC; 2007. http://www.cdc.gov/tb/ publications/guidelines/TB-HIV-Drugs/PDF/tbhiv.pdf. Accessed 25 August 2009
12. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach [revised]. Geneva: UN; 2006. http://www.who.int/hiv/pub/guidelines/artadultguidelines. pdf. Accessed 11 August 2009
13. Ramachandran G, Hemanth Kumar AK, Rajasekaran S, et al. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. Antimicrob Agents Chemother 2009; 53:863-868.
14. Cohen K, Grant A, Dandara C, et al. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516 GT polymorphism on efavirenz concentrations in adults in South Africa. Antiviral Ther 2009; 14:687-695.
15. Gross R, Aplenc R, Tenhave T, et al. Slow efavirenz metabolism genotype is common in Botswana. J Acquir Immune Defic Syndr 2008; 49:336-337.
16. Kwara A, Lartey M, Sagoe KW, et al. CYP2B6 (c.516G-T) and CYP2A6 (9B and/or 17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br J Clin Pharmacol 2009; 67:427-436.
17. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15:71-75. (Pubitemid 32055781)
18. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicinbased antitubercular therapy. JAMA 2008; 300:530-539.
19. Manosuthi W, Sungkanuparph S, Tantanathip P, et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis 2009; 48: 1752-1759.
20. Cohen K, van Cutsem G, Boulle A, et al. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. J Antimicrob Chemother 2008; 61:389-393.
21. Elsherbiny D, Cohen K, Jansson B, et al. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. Eur J Clin Pharmacol 2009; 65:71-80.
22. Avihingsanon A, Manosuthi W, Kantipong P, et al. Pharmacokinetics and 48- week efficacy of nevirapine: 400 mg versus 600mg per day in HIV-tuberculosis coinfection receiving rifampicin. Antiviral Ther 2008; 13:529-536.
23. Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 1998; 20:1071-1092.
24. Van Oosterhout JJG, Kumwenda JJ, Beadsworth M, et al. Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians. Antiviral Ther 2007; 12:515-521.
25. Laureillard D, Prak N, Fernandez M, et al. Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia. HIV Med 2008; 9:514-518.
26. Bhatt N, Baudin E, Jani IV, et al. Preliminary safety results of co-administration nevirapine (NVP) or efavirenz (EFV), and rifampicin (RMP) in HIV-tuberculosis (TB) coinfected patients in Maputo (Mozambique), ANRS 12146 (CARINEMO). In: Abstracts of the 5th IAS conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa; 2009; abstract MOPEB032.
27. Shipton LK, Wester CW, Stock S, et al. Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV coinfection in Botswana. Int J Tuberc Lung Dis 2009; 13:360-366.
28. ManosuthiW, Mankatitham W, Lueangniyomkul A, et al. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin. HIV Med 2008; 9:294-299.
29. La Porte CJ, Colbers EP, Bertz R, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004; 48:1553-1560.
30. Veldkamp AI, Hoetelmans RM, Beijnen JH, et al. Ritonavir enables combined therapy with rifampin and saquinavir. Clin Infect Dis 1999; 29:1586.
31. Rolla VC, Da Silva Vieira MA, Pereira Pinto D, et al. Safety, efficacy and pharmacokinetics of ritonavir 400 mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis. Clin Drug Investig 2006; 26:469-479.
32. Nijland HM, L'Homme RF, RongenGA, et al. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS 2008; 22:931-935.
33. Haas DW, Koletar SL, Laughlin L, et al. Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr 2009; 50:290-293.
34. Schmitt C, Riek M, Winters K, et al. Unexpected hepatotoxicity of rifampin and saquinavir/ritonavir in healthy male volunteers. Arch Drug Inf 2009; 2:8-16.
35. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-1861.
36. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167:1472-1477.
37. Marks DJ, Dheda K, Dawson R, et al. Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs. Int J STD AIDS 2009; 20:339-345.
38. Westreich DJ, Sanne I, Maskew M, et al. Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis 2009; 48:1617-1623.
39. Hoffmann CJ, Charalambous S, Thio CL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2007; 21:1301-1308.
40. Tansuphasawadikul S, Saito W, Kim J, et al. Outcomes in HIV-infected patients on antiretroviral therapy with tuberculosis. Southeast Asian J Trop Med Public Health 2007; 38:1053-1060.
41. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5:361-373.
42. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resourcelimited settings. Lancet Infect Dis 2008; 8:516-523.
43. Leone S, Nicastri E, Giglio S, et al. Immune reconstitution inflammatory syndrome associated with Mycobacterium tuberculosis infection: a systematic review. Int J Infect Dis 2009. [Epub ahead of print]
44. Lawn SD, Wilkinson RJ, Lipman MC, Wood R. Immune reconstitution and 'unmasking' of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 2008; 177:680-685.
45. Lawn SD, Wainwright H, Orrell C. Fatal unmasking tuberculosis immune reconstitution disease with bronchiolitis obliterans organizing pneumonia: the role of macrophages. AIDS 2009; 23:143-145.
46. Chen WL, Lin YF, Tsai WC, Tsao YT. Unveiling tuberculous pyomyositis: an emerging role of immune reconstitution inflammatory syndrome. Am J Emerg Med 2009; 27:251 e1-251 e2.
47. Tahir M, Sinha S, Sharma SK, Mitsuyasu RT. Immune reconstitution inflammatory syndrome manifesting as disseminated tuberculosis, deep venous thrombosis, encephalopathy and myelopathy. Indian J Chest Dis Allied Sci 2008; 50:363-364.
48. Bourgarit A, Carcelain G, Martinez V, et al. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 2006; 20:F1-7.
49. Meintjes G, Wilkinson KA, Rangaka MX, et al. Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med 2008; 178:1083-1089.
50. Manabe YC, Breen R, Perti T, et al. Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. J Infect Dis 2009; 199:437-444.
51. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158:157-161.
52. Breen RA, Smith CJ, Bettinson H, et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 2004; 59:704-707.
53. Breton G, Duval X, Estellat C, et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 2004; 39:1709-1712.
54. Burman W, Weis S, Vernon A, et al. Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. Int J Tuberc Lung Dis 2007; 11:1282-1289.
55. Kumarasamy N, Chaguturu S, Mayer KH, et al. Incidence of immune reconstitution syndrome in HIV/tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India. J Acquir Immune Defic Syndr 2004; 37:1574-1576.
56. Michailidis C, Pozniak AL, Mandalia S, et al. Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir Ther 2005; 10:417-422.
57. Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect 2006; 53:357-363.
58. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21:335-341.
59. Serra FC, Hadad D, Orofino RL, et al. Immune reconstitution syndrome in patients treated for HIV and tuberculosis in Rio de Janeiro. Braz J Infect Dis 2007; 11:462-465.
60. Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19:399-406.
61. Meintjes G, Rangaka MX, Maartens G, et al. Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis 2009; 48:667-676.
62. Lawn SD, Wood R. Hepatic involvement with tuberculosis-associated immune reconstitution disease. AIDS 2007; 21:2362-2363.
63. Wu SW, Chen CJ, Lin TY, Wang NC. Acute peritonitis as presentations of tuberculosis-associated immune reconstitution inflammatory syndrome in an HIV-infected man. Am J Med Sci 2008; 335:387-389.
64. Pepper DJ, Marais S, Maartens G, et al. Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin Infect Dis 2009; 48:e96-e107.
65. Weber E, Gunthard HF, Schertler T, Seebach JD. Spontaneous splenic rupture as manifestation of the immune reconstitution inflammatory syndrome in an HIV type 1 infected patient with tuberculosis. Infection 2009; 37:163-165.
66. Salliot C, Guichard I, Daugas E, et al. Acute kidney disease due to immune reconstitution inflammatory syndrome in an HIV-infected patient with tuberculosis. J Int Assoc Physicians AIDS Care (Chic Ill) 2008; 7:178-181.
67. Rapose A, Sarvat B, Sarria JC. Immune reconstitution inflammatory syndrome presenting as pericarditis and pericardial effusion. Cardiology 2008; 110: 142-144. (Pubitemid 351630041)
68. Wang SH, Menon A, Hyslop NE. Cardiac tamponade: an unusual complication of simultaneous treatment of tuberculosis and HIV. South Med J 2008; 101:558-560.
69. Pepper DJ, Rebe K, Morroni C, et al. Clinical deterioration during antitubercular treatment at a district hospital in South Africa: the importance of drug resistance and AIDS defining illnesses. PLoS One 2009; 4:e4520.
70. Meintjes G, Wilkinson RJ, Morroni C, et al. Randomised placebo-controlled trial of prednisone for the TB immune reconstitution inflammatory syndrome [abstract 34]. In: 16th Conference on Retroviruses and Opportunistic Infections. Montreal; 2009.
71. Elliott AM, Halwiindi B, Bagshawe A, et al. Use of prednisolone in the treatment of HIV-positive tuberculosis patients. Q J Med 1992; 85:855-860.
72. Elliott AM, Luzze H, Quigley MA, et al. A randomized, double-blind, placebocontrolled trial of the use of prednisolone as an adjunct to treatment in HIV-1- associated pleural tuberculosis. J Infect Dis 2004; 190:869-878.
73. Volkow PF, Cornejo P, Zinser JW, et al. Life-threatening exacerbation of Kaposi's sarcoma after prednisone treatment for immune reconstitution inflammatory syndrome. AIDS 2008; 22:663-665.
74. Schiffer JT, Sterling TR. Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis. J Acquir Immune Defic Syndr 2007; 44:229-234.
75. Lawn SD, Wood R. Optimum time to initiate antiretroviral therapy in patients with HIV-associated tuberculosis: there may be more than one right answer. J Acquir Immune Defic Syndr 2007; 46:121-123; author reply 123.
76. Fairall LR, Bachmann MO, Louwagie GM, et al. Effectiveness of antiretroviral treatment in a South African program: a cohort study. Arch Intern Med 2008; 168:86-93.
77. Lawn SD, Myer L, Orrell C, et al. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005; 19:2141-2148.
78. Chilton D, Edwards SG, Pellegrino P, Miller RF. Factors influencing delay in initiating antiretroviral therapy among HIV infected patients coinfected with tuberculosis. Thorax 2008; 63:935-936.
79. Friedland G. Tuberculosis immune reconstitution inflammatory syndrome: drug resistance and the critical need for better diagnostics. Clin Infect Dis 2009; 48:677-679.
80. Velasco M, Castilla V, Sanz J, et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 2009; 50:148-152.
81. Tabarsi P, Tehrani AS, Baghaei P, et al. Early initiation of antiretroviral therapy results in decreased morbidity and mortality among patients with TB and HIV. J Int AIDS Soc 2009; 12:14.
82. Blanc FX, Havlir DV, Onyebujoh PC, et al. Treatment strategies for HIVinfected patients with tuberculosis: ongoing and planned clinical trials. J Infect Dis 2007; 196 (Suppl 1):S46-S51.
83. Karim SA, Naidoo K, Grobler A, et al. Initiating ART during TB treatment significantly increases survival: results of a randomized controlled clinical trial in TB/HIV-coinfected patients in South Africa [abstract 36a]. In: 16th Conference on Retroviruses and Opportunistic Infections. Montreal; 2009.
84. Haar CH, Cobelens FG, Kalisvaart NA, et al. HIV-related mortality among tuberculosis patients in The Netherlands, 1993-2001. Int J Tuberc Lung Dis 2007; 11:1038-1041.
85. Sanguanwongse N, Cain KP, Suriya P, et al. Antiretroviral therapy for HIVinfected tuberculosis patients saves lives but needs to be used more frequently in Thailand. J Acquir Immune Defic Syndr 2008; 48:181-189.
86. Akksilp S, Karnkawinpong O, Wattanaamornkiat W, et al. Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand. Emerg Infect Dis 2007; 13:1001-1007.
87. Moore D, Liechty C, Ekwaru P, et al. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS 2007; 21:713-719.
88. Westreich D, MacPhail P, Van Rie A, et al. Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS 2009; 23:707-715.
89. Koenig SP, Riviere C, Leger P, et al. High mortality among patients with AIDS who received a diagnosis of tuberculosis in the first 3 months of antiretroviral therapy. Clin Infect Dis 2009; 48:829-831.
90. Gandhi NR, Moll AP, Lalloo U, et al. Successful integration of tuberculosis and HIV treatment in rural South Africa: the Sizonq'oba study. J Acquir Immune Defic Syndr 2009; 50:37-43.
91. Harris JB, Hatwiinda SM, Randels KM, et al. Early lessons from the integration of tuberculosis and HIV services in primary care centers in Lusaka, Zambia. Int J Tuberc Lung Dis 2008; 12:773-779.
92. Havlir DV, Getahun H, Sanne I, Nunn P. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA 2008; 300:423-430.